{"id":"i-v-mannitol","safety":{"commonSideEffects":[{"rate":null,"effect":"Dehydration and electrolyte imbalance"},{"rate":null,"effect":"Hypernatremia"},{"rate":null,"effect":"Rebound intracranial pressure elevation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Thrombophlebitis at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mannitol is a sugar alcohol that creates an osmotic gradient, pulling water from the extravascular and intracellular compartments into the blood vessels and then into the urine. This reduces cerebral edema and intracranial pressure by decreasing brain water content, and similarly reduces intraocular pressure. It is administered intravenously and acts rapidly to promote diuresis while maintaining or expanding plasma volume.","oneSentence":"Mannitol is an osmotic diuretic that draws fluid from tissues into the intravascular space and increases urine output to reduce intracranial and intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:39.554Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cerebral edema and elevated intracranial pressure"},{"name":"Acute glaucoma and elevated intraocular pressure"},{"name":"Oliguria and acute kidney injury (renal protective agent)"}]},"trialDetails":[{"nctId":"NCT01681953","phase":"PHASE3","title":"A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis","status":"COMPLETED","sponsor":"Zymenex A/S","startDate":"2012-08","conditions":"Alpha-Mannosidosis","enrollment":25},{"nctId":"NCT00042367","phase":"NA","title":"Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2000-04-04","conditions":"Brain Tumors","enrollment":119},{"nctId":"NCT00958022","phase":"PHASE1","title":"Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Ahmad Tarhini","startDate":"2009-09","conditions":"Small Cell Lung Cancer","enrollment":7},{"nctId":"NCT00397501","phase":"PHASE1, PHASE2","title":"BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2013-10","conditions":"Brain and Central Nervous System Tumors, Breast Cancer, Cognitive/Functional Effects","enrollment":""},{"nctId":"NCT00238173","phase":"PHASE1","title":"Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-12","conditions":"Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ","enrollment":2},{"nctId":"NCT02517788","phase":"PHASE1","title":"Phase I BP Interferon (IFN) Beta-004","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2006-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":24},{"nctId":"NCT02091180","phase":"PHASE4","title":"Mannitol Improves Cerebral Oxygen Saturation","status":"COMPLETED","sponsor":"Imam Abdulrahman Bin Faisal University","startDate":"2013-01","conditions":"Anesthesia","enrollment":40},{"nctId":"NCT00439244","phase":"PHASE3","title":"Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Osteoporosis","enrollment":412},{"nctId":"NCT00426192","phase":"PHASE4","title":"Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression","status":"UNKNOWN","sponsor":"University Hospital, Saarland","startDate":"2003-10","conditions":"Inflammation","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"i.v. mannitol","genericName":"i.v. mannitol","companyName":"University Hospital, Saarland","companyId":"university-hospital-saarland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mannitol is an osmotic diuretic that draws fluid from tissues into the intravascular space and increases urine output to reduce intracranial and intraocular pressure. Used for Cerebral edema and elevated intracranial pressure, Acute glaucoma and elevated intraocular pressure, Oliguria and acute kidney injury (renal protective agent).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}